The inhibitory effect of celecoxib on mouse hepatoma H22 cell line on the arachidonic acid metabolic pathway 1

Biochemistry and Cell Biology

Volumn 88, Issue 4, 2010, Pages 603-609

  Xu, Zhigang ^a   Zhang, Ming ^a   Lv, Xiaoyan ^a   Xiang, Dan ^a   Zhang, Xuewen ^b   Chen, Li ^a  

^a Basic Medical College   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

Arachidonic acid; Celecoxib; Cyclooxygenase 2; Cytosolic phospholipase A2; Prostaglandin E2

Indexed keywords

ARACHIDONIC ACIDS; CELECOXIB; CYCLOOXYGENASE 2; CYTOSOLIC PHOSPHOLIPASE; PROSTAGLANDINE;

ACIDS; METABOLISM; PROTEINS;

CELL CULTURE;

ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYTOSOLIC PHOSPHOLIPASE A2; MESSENGER RNA; PROSTAGLANDIN E2;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ARACHIDONIC ACID; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; LIVER NEOPLASMS; METABOLIC NETWORKS AND PATHWAYS; MICE; PHOSPHOLIPASES A2; PYRAZOLES; SULFONAMIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 77954910392     PISSN: 08298211     EISSN: 12086002     Source Type: Journal    
DOI: 10.1139/O09-184     Document Type: Article

References (39)

1. Bae, S.H., Jung, E.S., Park, Y.M., Kim, B.S., Kim, B.K., Kim, D.G., and Ryu, W.S. 2001. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin. Cancer Res. 7(5): 1410-1418. PMID:11350912.
2. Balsinde, J., Balboa, M.A., Insel, P.A., and Dennis, E.A. 1999. Regulation and inhibition of phospholipase A2. Annu. Rev. Pharmacol. Toxicol. 39(1): 175-189. doi:10.1146/annurev. pharmtox.39.1.175. PMID:10331081.
3. Baron, J.A. 2003. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog. Exp. Tumor Res. 37: 1-24.doi:10.1159/ 000071364. PMID:12795046.
4. Behari, J., Zeng, G., Otruba, W., Thompson, M.D., Muller, P., Micsenyi, A., et al. 2007. R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells. J. Hepatol. 46(5): 849-857. doi:10.1016/j.jhep.2006.11.017. PMID: 17275129.
5. Bonovas, S., Tsantes, A., Drosos, T., and Sitaras, N.M. 2008. Cancer chemoprevention: a summary of the current evidence. Anticancer Res. 28(3B 3B): 1857-1866. PMID:18630472.
6. Cheng, J., Imanishi, H., Amuro, Y., and Hada, T. 2002. NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines. Int. J. Cancer, 99(5): 755-761.doi:10.1002/ijc.10409. PMID:12115513.
7. Cui, W., Yu, C.H., and Hu, K.Q. 2005. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin. Cancer Res. 11(22): 8213-8221. doi:10.1158/1078-0432.CCR-05-1044.PMID:16299255.
8. Cui, W., Hu, S.X., Tang, Z.Y., and Hu, K.Q. 2008. In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX-2-deleted human HCC xenografts in nude mice. Anticancer Drugs, 19(9): 891-897. doi:10.1097/CAD.0b013e32830ef8ca. PMID:18766003.
9. Dommels, Y.E., Haring, M.M., Keestra, N.G., Alink, G.M., van Bladeren, P.J., and van Ommen, B. 2003. The role of cyclooxy-genase in n-6 and n-3 polyunsaturated fatty acid mediated effects on cell proliferation, PGE(2) synthesis and cytotoxicity in human colorectal carcinoma cell lines. Carcinogenesis, 24(3): 385-392. doi:10.1093/carcin/24.3.385. PMID:12663496.
10. Fosslien, E. 2000. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit. Rev. Clin. Lab. Sci. 37(5): 431-502. doi:10.1080/10408360091174286. PMID:11078056.
11. Grosch, S., Maier, T.J., Schiffmann, S., and Geisslinger, G. 2006. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic ef-fects of selective COX-2 inhibitors. J. Natl. Cancer Inst. 98(11): 736-747. PMID:16757698.
12. Gupta, R.A., and Dubois, R.N. 2001. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer, 1(1): 11-21. doi:10.1038/35094017. PMID:11900248.
13. Han, C., Demetris, A.J., Michalopoulos, G., Shelhamer, J.H., and Wu, T. 2002. 85-kDa cPLA(2) plays a critical role in PPAR-mediated gene transcription in human hepatoma cells. Am. J. Physiol. Gastrointest. Liver Physiol. 282(4): 586-597. PMID:11897617.
14. Han, C., Michalopoulos, G.K., and Wu, T. 2006. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine ki-nases and enhances invasiveness in human hepatocellular carcinoma cells. J. Cell. Physiol. 207(1): 261-270.doi:10.1002/jcp. 20560. PMID:16331686.
15. Huang, Z.-J., Xu, G., Li, Y.-L., and Lao, G.-C. 2004. Determination of free fatty acids in rat plasma by HPLC. Acad. J. Guangdong Coll. Pharm. 20: 656-658.
16. Ikeda, T., Tozuka, S., Hasumura, Y., and Takeuchi, J. 1988. Prostaglandin-E-producing hepatocellular carcinoma with hypercalcemia. Cancer, 61(9): 1813-1814. doi:10.1002/1097-0142(19880501) 61:9<1813::AID-CNCR2820610915>3.0.CO;2-U. PMID:2833340.
17. Kashfi, K., and Rigas, B. 2005. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem. Pharmacol. 70(7): 969-986. doi:10.1016/j.bcp.2005. 05.004. PMID:15949789.
18. Kern, M.A., Schubert, D., Sahi, D., Schoneweiss, M.M., Moll, I., Haugg, A.M., et al. 2002. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology, 36(4 Pt 1): 885-894. PMID:12297835.
19. Khammanit, R., Chantakru, S., Kitiyanant, Y., and Saikhun, J. 2008. Effect of serum starvation and chemical inhibitors on cell cycle synchronization of canine dermal fibroblasts. Theriogenology, 70(1): 27-34. doi:10.1016/j.theriogenology.2008.02.015. PMID:18423836.
20. Koga, H., Sakisaka, S., Ohishi, M., Kawaguchi, T., Taniguchi, E., Sasatomi, K., et al. 1999. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology, 29(3): 688-696. doi:10.1002/hep.510290355. PMID:10051469.
21. Kondo, M., Yamamoto, H., Nagano, H., Okami, J., Ito, Y., Shimizu, J., et al. 1999. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin. Cancer Res. 5(12): 4005-4012. PMID:10632332.
22. Kurosawa, T., Nakamura, H., Yamaura, E., Fujino, H., Matsuzawa, Y., Kawashima, T., and Murayama, T. 2009. Cytotoxicity induced by inhibition of thioredoxin reductases via multiple signaling pathways: role of cytosolic phospholipase A(2)alpha-dependent and - independent release of arachidonic acid. J. Cell. Physiol. 219(3): 606-616. doi:10.1002/jcp.21703. PMID:19170071.
23. Leng, J., Han, C., Demetris, A.J., Michalopoulos, G.K., and Wu, T. 2003. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology, 38(3): 756-768. doi:10.1053/jhep.2003.50380. PMID:12939602.
24. Li, B., Gu, L., Zhang, H., Huang, J., Chen, Y., Hertz, L., and Peng, L. 2007. Up-regulation of cPLA(2) gene expression in astrocytes by all three conventional anti-bipolar drugs is drug-specific and enzyme-specific. Psychopharmacology (Berl.), 194(3): 333-345. doi:10.1007/s00213-007-0853-5. PMID:17594078.
25. Liu, N.B., Peng, T., Pan, C., Yao, Y.Y., Shen, B., and Leng, J. 2005. Overexpression of cyclooxygenase-2 in human HepG2, Bel-7402 and SMMC-7721 hepatoma cell lines and mechanism of cyclooxygenase-2 selective inhibitor celecoxib-induced cell growth inhibition and apoptosis. World J. Gastroenterol. 11(40): 6281-6287. PMID:16419156.
26. Maier, T.J., Schilling, K., Schmidt, R., Geisslinger, G., and Grosch, S. 2004. Cyclooxygenase-2 (COX-2)-dependent and -indepen-dent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem. Pharmacol. 67(8): 1469-1478. doi:10. 1016/j.bcp.2003.12.014. PMID:15041464.
27. Murakami, M., and Kudo, I. 2002. Phospholipase A2. J. Biochem. 131(3): 285-292. PMID:11872155.
28. Nakanishi, M., and Rosenberg, D.W. 2006. Roles of cPLA2alpha and arachidonic acid in cancer. Biochim. Biophys. Acta, 1761(11): 1335-1343. PMID:17052951.
29. Niederberger, E., Tegeder, I., Vetter, G., Schmidtko, A., Schmidt, H., Euchenhofer, C., et al. 2001. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB. FASEB J. 15(9): 1622-1624. PMID:11427506.
30. Parkin, D.M., Bray, F., Ferlay, J., and Pisani, P. 2001. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer, 94(2): 153-156. doi:10.1002/ijc.1440. PMID:11668491.
31. Schonthal, A.H. 2007a. Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br. J. Cancer, 97(11): 1465-1468. doi:10.1038/sj.bjc.6604049. PMID: 17955049.
32. Schonthal, A.H. 2007b. Induction of apoptosis by celecoxib in cell culture: an uncertain role for cyclooxygenase-2. Cancer Res. 67(11): 5575-5576, author reply 5576. doi:10.1158/0008-5472. CAN-06-3414. PMID:17545641.
33. Scorrano, L., Penzo, D., Petronilli, V., Pagano, F., and Bernardi, P. 2001. Arachidonic acid causes cell death through the mitochondrial permeability transition. Implications for tumor necrosis factor-alpha aopototic signaling. J. Biol. Chem. 276(15): 12035-12040. doi:10.1074/jbc.M010603200. PMID:11134037.
34. Shin, S.M., and Kim, S.G. 2009. Inhibition of arachidonic acid and iron-induced mitochondrial dysfunction and apoptosis by oltipraz and novel 1,2-dithiole-3-thione congeners. Mol. Pharmacol. 75(1): 242-253. doi:10.1124/mol.108.051128. PMID:18945820.
35. Shiota, G., Okubo, M., Noumi, T., Noguchi, N., Oyama, K., Takano, Y., et al. 1999. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology, 46(25): 407-412. PMID:10228831.
36. Smith, W.L., and Langenbach, R. 2001. Why there are two cyclooxygenase isozymes. J. Clin. Invest. 107(12): 1491-1495. doi:10.1172/JCI13271. PMID:11413152.
37. Sultan, A., and Sokolove, P.M. 2001. Free fatty acid effects on mitochondrial permeability: an overview. Arch. Biochem. Biophys. 386(1): 52-61. doi:10.1006/abbi.2000.2195. PMID:11361000.
38. Tang, B.D., Zhou, Q., Lin, Q.H., and Liu, S.C. 2007. [Inhibitory effects of cyclooxygenase-2 inhibitor celecoxib on the proliferation of hepatocellular carcinoma cells]. Nan Fang Yi Ke Da Xue Xue Bao, 27(10): 1511-1513. PMID:17959527.
39. Wu, T. 2006. Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat. Rev. 32(1): 28-44. doi:10.1016/j.ctrv.2005.10.004. PMID:16337744.